{"DataElement":{"publicId":"11346884","version":"1","preferredName":"Lung Non-Small Cell Carcinoma Most Recent Line of Therapy PD1 Inhibitor PD-1 Ligand Inhibitor Include Yes No Coded Indicator","preferredDefinition":"The response indicating whether or not the most recently NSCLC line of therapy included PD-1 inhibitors or PD-1 ligand inhibitors.","longName":"NSCLC_PD1_PDL1_IND","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"11346811","version":"1","preferredName":"Lung Non-Small Cell Carcinoma Most Recent Line of Therapy PD1 Inhibitor PD-1 Ligand Inhibitor Include","preferredDefinition":"A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy._Nearest to the present._The sequence of therapies administered to a patient.:An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system._Any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (PD-1; PD1); programmed death ligand 1 (PD-L1; CD274) and 2 (PD-L2; CD273)._Add as part of something else; put in as part of a set, group, or category.","longName":"11346809v1.00:11346810v1.00","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"11346809","version":"1","preferredName":"Lung Non-Small Cell Carcinoma Most Recent Line of Therapy","preferredDefinition":"A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy._Nearest to the present._The sequence of therapies administered to a patient.","longName":"C2926:C25577:C133518","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Non-Small Cell Carcinoma","conceptCode":"C2926","definition":"A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Most Recent","conceptCode":"C25577","definition":"Nearest to the present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Line of Therapy","conceptCode":"C133518","definition":"The sequence of therapies administered to a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9EE7954-336A-76F7-E053-731AD00A765B","latestVersionIndicator":"Yes","beginDate":"2022-09-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-30","modifiedBy":"GDEEN","dateModified":"2022-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"11346810","version":"1","preferredName":"PD1 Inhibitor PD-1 Ligand Inhibitor Include","preferredDefinition":"An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system._Any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (PD-1; PD1); programmed death ligand 1 (PD-L1; CD274) and 2 (PD-L2; CD273)._Add as part of something else; put in as part of a set, group, or category.","longName":"C124946:C156893:C74521","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PD1 Inhibitor","conceptCode":"C124946","definition":"An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"PD-1 Ligand Inhibitor","conceptCode":"C156893","definition":"Any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (PD-1; PD1); programmed death ligand 1 (PD-L1; CD274) and 2 (PD-L2; CD273).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Include","conceptCode":"C74521","definition":"Add as part of something else; put in as part of a set, group, or category.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9EE7954-336B-76F7-E053-731AD00A765B","latestVersionIndicator":"Yes","beginDate":"2022-09-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-30","modifiedBy":"GDEEN","dateModified":"2022-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9EE7954-336C-76F7-E053-731AD00A765B","latestVersionIndicator":"Yes","beginDate":"2022-09-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-30","modifiedBy":"GDEEN","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":"10.03.22_Curated to support protocol S2302_ghd","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2183836","version":"1","preferredName":"Yes No Coded Indicator","preferredDefinition":"Yes or No response to a question coded as 1 (Yes) or 2 (No).","longName":"YES_NO_CD_IND","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1","valueDescription":"Yes","ValueMeaning":{"publicId":"2567168","version":"1","preferredName":"Yes","longName":"2567168","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":"12/29/2006 - Updated with NCI Thesaurus definition.","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA5257DC-29DC-1EEB-E034-0003BA12F5E7","beginDate":"2003-11-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-20","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA5257DC-29DE-1EEB-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-20","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2183782","version":"1","preferredName":"NCIP","preferredDefinition":"Cancer Biomedical Informatics Grid","longName":"NCIP","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DACB2549-3BE3-73F7-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA5257DC-29D8-1EEB-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-20","modifiedBy":"REEVESD","dateModified":"2014-08-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Did the most recent line of therapy for NSCLC include anti-PD-1 or anti-PD-L1 therapy?","url":null,"context":"SWOG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9EEAE8D-F8A0-7C88-E053-731AD00A5BB2","latestVersionIndicator":"Yes","beginDate":"2022-09-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-30","modifiedBy":"GDEEN","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":"10.03.22_Curated to support protocol S2302_ghd","unresolvedIssues":null,"deletedIndicator":"No"}}